Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annovis BioFRA:07X +0.65%39 EV-to-EBITDA is -1.46 as of Aug. 16, 2026. GuruFocus rates FRA:07X with a GF Score™ of 39/100. The stock has 1 warning sign investors should review. Among 402 Biotechnology companies, Annovis Bio ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Annovis Bio's enterprise value is €52.00 Mil.
Annovis Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-35.64 Mil. Therefore, Annovis Bio's EV-to-EBITDA for today is -1.46.
The historical rank and industry rank for Annovis Bio's EV-to-EBITDA or its related term are showing as below:
FRA:07X'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.56 Med: 0 Max: 0
Current: -1.56
FRA:07X's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.825
vs FRA:07X: -1.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annovis Bio's PE Ratio (TTM) for today is calculated as:
Annovis Bio's share price for today is €1.54.
Annovis Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Annovis Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:07X vs IBIO, ENLV, ATRA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Annovis Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annovis Bio EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annovis Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Annovis Bio's EV-to-EBITDA falls into.
Annovis Bio's current Enterprise Value is €52.00 Mil.
Annovis Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-35.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annovis Bio (FRA:07X) has a EV-to-EBITDA of -1.46 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Annovis Bio. According to the industry distribution chart, Annovis Bio ranks #999999 out of 402 companies in the Biotechnology industry.
Is Annovis Bio's EV-to-EBITDA too high?
Annovis Bio's current EV-to-EBITDA is -1.46. Based on the distribution chart, Annovis Bio ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annovis Bio has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's EV-to-EBITDA compare to IBIO and ENLV?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #999999 out of 402 companies for EV-to-EBITDA. This places Annovis Bio in the lower half of its industry. The industry median EV-to-EBITDA is 13.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.83, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Annovis Bio. For the Biotechnology industry, the median EV-to-EBITDA is 13.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current EV-to-EBITDA is -1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current EV-to-EBITDA of -1.46. The current EV-to-EBITDA is -1.46. Annovis Bio's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current EV-to-EBITDA is -1.46 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
39GF Score
Get the complete analysis for FRA:07X
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:07X has been successfully added to your 
